Have you started your API v2 Migration yet? It must be started before April 30, 2024. Contact your account manager today. Learn More

Event
09.12.23 - 09.13.23 | 9am-4pm

DEA Public Listening Sessions on Telemedicine Regulations

DEA Hosts Public Listening Sessions on Telemedicine Regulations –
MEDIA ADVISORY

The DEA will be hosting listening sessions to receive additional input concerning the practice of telemedicine with regards to controlled substances.

This event will cover:

Space is limited. In-person attendance and/or the ability to present are not guaranteed upon registration. DEA will be processing registrations and you will be notified as to the status of your request.

Beginning on August 7, members of the public wishing to attend in person (space permitting) must register HERE by August 21, 2023 at 11:59 p.m.

Current Rulings

The current temporary extension has a deadline of November 11, 2023. The DEA stated that it plans to release “one or more final rules” that build off its initial two proposed rules before this deadline that can be implemented by November 11, 2024; however, it is unclear at this time if the agency will meet this deadline. Any new rules that the DEA promulgates on the remote prescribing of controlled substances are expected to be permanent.

The agency continues to emphasize that they are focused on allowing the practice of telemedicine in a manner that aligns with public health and safety objectives while ensuring effective measures against diversion.

Federal Register – Full Text of Temporary Ruling
Timeline of changes to EPCS for telemedicine in 2023
DEA Timeline of Telemedicine Flexibilities Infographic – Download
EPCS DEA Regulatory Blog

DEA Temporarily Extends Telemedicine Flexibilities for the Prescribing of Controlled Substances

Throughout the COVID-19 pandemic, the Drug Enforcement Administration (DEA) granted providers the flexibility to prescribe clinically appropriate controlled substance medications without requiring an in-person visit, which was particularly crucial amidst the global shutdown. However, this allowance was contingent upon the Public Health Emergency (PHE) declared by the U.S. Health and Human Services (HHS) Secretary being in effect and was scheduled to be rescinded when it ended on May 11, 2023. With one day to spare on May 10, the DEA and the Substance Abuse and Mental Health Services Administration (SAMHSA) released a temporary rule extending the pandemic prescribing flexibility until November 11, 2023.